Drug Profile
Research programme: antisense cancer therapeutics - Antisense Pharma
Alternative Names: AP 11014; AP 15000; AP 15012Latest Information Update: 07 Nov 2013
Price :
$50
*
At a glance
- Originator Antisense Pharma
- Developer Isarna Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Nov 2013 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 08 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section
- 04 Jul 2003 Preclinical trials in Cancer in Germany (unspecified route)